Immunological evaluation of mannosylated chitosan nanoparticles based foot and mouth disease virus DNA vaccine, pVAC FMDV VP1–OmpA in guinea pigs

Nanda, Raj Kishore; Hajam, Irshad Ahmed; Edao, Bedaso Mammo; Kalaivanan, Ramya; Rajangam, Mageswary; Sekar, S. Chandra; Kondabattula, Ganesh; Bhanuprakash, V.; Kishore, Subodh

doi:10.1016/j.biologicals.2014.01.002

Cited by 37 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Iranian scientists found that the inclusion of inactivated FMDV into chitosan nanoparticles for intranasal application seemed effective in guinea pig models (Tajdini et al., ). Further improvements might be made by targeting the chitosan nanoparticles to antigen‐presenting cells within the mucosa via their mannose receptors (Nanda et al., ).…”

Section: Literature Reviewmentioning

confidence: 99%

Global Foot-and-Mouth Disease Research Update and Gap Analysis: 3 - Vaccines

Robinson

Knight-Jones

Charleston

et al. 2016

Transbound Emerg Dis

View full text Add to dashboard Cite

SummaryThis study assessed research knowledge gaps in the field of FMDV (foot-andmouth disease virus) vaccines. The study took the form of a literature review combined with research updates collected in 2014 from 33 institutes from across the world. Findings were used to identify priority areas for future FMD vaccine research. Vaccines play a vital role in FMD control, used both to limit the spread of the virus during epidemics in FMD-free countries and as the mainstay of disease management in endemic regions, particularly where sanitary controls are difficult to apply. Improvements in the performance or cost-effectiveness of FMD vaccines will allow more widespread and efficient disease control. FMD vaccines have changed little in recent decades, typically produced by inactivation of whole virus, the quantity and stability of the intact viral capsids in the final preparation being key for immunogenicity. However, these are exciting times and several promising novel FMD vaccine candidates have recently been developed. This includes the first FMD vaccine licensed for manufacture and use in the USA; this adenovirus-vectored FMD vaccine causes in vivo expression of viral capsids in vaccinated animals. Another promising vaccine candidate comprises stabilized empty FMDV capsids produced in vitro in a baculovirus expression system. Recombinant technologies are also being developed to improve otherwise conventionally produced inactivated vaccines, for example, by creating a chimeric vaccine virus to increase capsid stability and by inserting sequences into the vaccine virus for desired antigen expression. Other important areas of ongoing research include enhanced adjuvants, vaccine quality control procedures and predicting vaccine protection from immune correlates, thus reducing dependency on animal challenge studies. Globally, the degree of independent vaccine evaluation is highly variable, and this is essential for vaccine quality. Previously neglected, the importance of evaluating vaccination programme effectiveness and impact is increasingly being recognized.

show abstract

Section: Literature Reviewmentioning

confidence: 99%

Global Foot-and-Mouth Disease Research Update and Gap Analysis: 3 - Vaccines

Robinson

Knight-Jones

Charleston

et al. 2016

Transbound Emerg Dis

View full text Add to dashboard Cite

show abstract

“…We recently developed assays to detect and quantify HSV-specific antibody secreting cells in lymphoid and peripheral tissues of HSV-2 infected guinea pigs (Milligan et al, 2005; Xia et al, 2014). Cell-mediated responses have been assessed previously in other immunization systems as the antigen-specific proliferation of lymphocyte populations from immune animals through the use of 3 H thymidine uptake assays (Cho and McMurray, 2007) or MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) dye-based proliferation assays (Nanda et al, 2014; Terhuja et al, 2015). Previous studies by others in an HSV-2 model utilized a novel cytotolytic assay and 3 H thymidine uptake assays to characterize cell-mediated responses of guinea pigs to therapeutic immunization during the early stages of HSV-2 latency (Bernstein et al, 1991).…”

Section: Discussionmentioning

confidence: 99%

Detection of herpes simplex virus type 2 (HSV-2) -specific cell-mediated immune responses in guinea pigs during latent HSV-2 genital infection

Perry

Banasik

Gorder

et al. 2016

Journal of Immunological Methods

View full text Add to dashboard Cite

Genital infections with herpes simplex virus type 2 (HSV-2) are a source of considerable morbidity and are a health concern for newborns exposed to virus during vaginal delivery. Additionally, HSV-2 infection diminishes the integrity of the vaginal epithelium resulting in increased susceptibility of individuals to infection with other sexually transmitted pathogens. Understanding immune protection against HSV-2 primary infection and immune modulation of virus shedding events following reactivation of the virus from latency is important for the development of effective prophylactic and therapeutic vaccines. Although the murine model of HSV-2 infection is useful for understanding immunity following immunization, it is limited by the lack of spontaneous reactivation of HSV-2 from latency. Genital infection of guinea pigs with HSV-2 accurately models the disease of humans including the spontaneous reactivation of HSV-2 from latency and provides a unique opportunity to examine virus-host interactions during latency. Although the guinea pig represents an accurate model of many human infections, relatively few reagents are available to study the immunological response to infection. To analyze the cell-mediated immune response of guinea pigs at extended periods of time after establishment of HSV-2 latency, we have modified flow-cytometry based proliferation assays and IFN-γ ELISPOT assays to detect and quantify HSV-specific cell-mediated responses during latent infection of guinea pigs. Here we demonstrate that a combination of proliferation and ELISPOT assays can be used to quantify and characterize effecter function of virus-specific immune memory responses during HSV-latency.

show abstract

“…BG also effectively target DNA vaccines to APC at mucosal surfaces. DNA vaccines generally possess low immunogenicity, require high dosage, and are not delivered in the context of an adequate danger signal [11, 83, 84]. Studies have shown that BG act as natural agonists and effectively target DNA vaccines to DC and also increased their transfection efficiencies many folds [10, 18, 78].…”

Section: Bg As Mucosal Vaccinesmentioning

confidence: 99%

“…These next generation vaccines, however, are poorly immunogenic in nature as compared to traditional vaccines, and therefore necessitate an appropriate adjuvant in the vaccine formulation. Furthermore, DNA vaccines are not effectively targeted to the antigen presenting cells (APC) and are not presented properly in the context of appropriate danger signals [10, 11]. Therefore, DNA-based vaccines need a better delivery system to reach their full potential.…”

Section: Introductionmentioning

confidence: 99%

Bacterial ghosts as adjuvants: mechanisms and potential

Hajam

Dar

Won

et al. 2017

Vet Res

View full text Add to dashboard Cite

Bacterial ghosts (BG) are empty cell envelopes derived from Gram-negative bacteria. They contain many innate immunostimulatory agonists, and are potent activators of a broad range of cell types involved in innate and adaptive immunity. Several considerable studies have demonstrated the effectiveness of BG as adjuvants as well as their ability to induce proinflammatory cytokine production by a range of immune and non-immune cell types. These proinflammatory cytokines trigger a generalized recruitment of T and B lymphocytes to lymph nodes that maximize the chances of encounter with their cognate antigen, and subsequent elicitation of potent immune responses. The plasticity of BG has allowed for the generation of envelope-bound foreign antigens in immunologically active forms that have proven to be effective vaccines in animal models. Besides their adjuvant property, BG also effectively deliver DNA-encoded antigens to dendritic cells, thereby leading to high transfection efficiencies, which subsequently result in higher gene expressions and improved immunogenicity of DNA-based vaccines. In this review, we summarize our understanding of BG interactions with the host immune system, their exploitation as an adjuvant and a delivery system, and address important areas of future research interest.

show abstract

Immunological evaluation of mannosylated chitosan nanoparticles based foot and mouth disease virus DNA vaccine, pVAC FMDV VP1–OmpA in guinea pigs

Cited by 37 publications

References 18 publications

Global Foot-and-Mouth Disease Research Update and Gap Analysis: 3 - Vaccines

Global Foot-and-Mouth Disease Research Update and Gap Analysis: 3 - Vaccines

Detection of herpes simplex virus type 2 (HSV-2) -specific cell-mediated immune responses in guinea pigs during latent HSV-2 genital infection

Bacterial ghosts as adjuvants: mechanisms and potential

Contact Info

Product

Resources

About